drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00277 | DB01285 | 1,031 | 708 | [
"DDInter1791",
"DDInter445"
] | Theophylline | Corticotropin | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1031,
24,
708
]
],
[
[
1031,
24,
455
],
[
455,
23,
708
]
],
[
[
1031,
24,
659
],
[
659,
62,
708
]
],
[
[
1031,
64,
88
],
[
88,
2... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and V... |
DB00012 | DB01041 | 1,535 | 770 | [
"DDInter479",
"DDInter1789"
] | Darbepoetin alfa | Thalidomide | Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
1535,
25,
770
]
],
[
[
1535,
25,
1668
],
[
1668,
1,
770
]
],
[
[
1535,
25,
350
],
[
350,
63,
770
]
],
[
[
1535,
24,
1514
],
[
1514,
... | [
[
[
"Darbepoetin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Darbepoetin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
],
[
"Lenalidomi... | Darbepoetin alfa may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound)
Darbepoetin alfa may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate... |
DB00184 | DB00863 | 763 | 1,194 | [
"DDInter1290",
"DDInter1568"
] | Nicotine | Ranitidine | Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Minor | 0 | [
[
[
763,
23,
1194
]
],
[
[
763,
23,
1127
],
[
1127,
1,
1194
]
],
[
[
763,
6,
8374
],
[
8374,
45,
1194
]
],
[
[
763,
21,
28701
],
[
28701,
... | [
[
[
"Nicotine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
]
],
[
[
"Nicotine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nizatidine"
],
[
"Niz... | Nicotine may cause a minor interaction that can limit clinical effects when taken with Nizatidine and Nizatidine (Compound) resembles Ranitidine (Compound)
Nicotine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ranitidine (Compound)
Nicotine (Compound) causes Discomfort (Side Effect) and Discomfort (Side... |
DB08882 | DB09291 | 1,281 | 741 | [
"DDInter1070",
"DDInter1615"
] | Linagliptin | Rolapitant | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
1281,
24,
741
]
],
[
[
1281,
63,
924
],
[
924,
24,
741
]
],
[
[
1281,
24,
1241
],
[
1241,
24,
741
]
],
[
[
1281,
24,
214
],
[
214,
... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
],
[... | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole and... |
DB01015 | DB09122 | 1,247 | 1,613 | [
"DDInter1724",
"DDInter1409"
] | Sulfamethoxazole | Peginterferon beta-1a | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1247,
24,
1613
]
],
[
[
1247,
62,
600
],
[
600,
24,
1613
]
],
[
[
1247,
63,
267
],
[
267,
24,
1613
]
],
[
[
1247,
23,
351
],
[
351,
... | [
[
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flucon... | Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB04855 | DB12500 | 540 | 283 | [
"DDInter602",
"DDInter714"
] | Dronedarone | Fedratinib | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
540,
24,
283
]
],
[
[
540,
23,
466
],
[
466,
62,
283
]
],
[
[
540,
25,
351
],
[
351,
23,
283
]
],
[
[
540,
63,
1419
],
[
1419,
2... | [
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Dronedarone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
... | Dronedarone may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Dronedarone may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may caus... |
DB01234 | DB14840 | 1,220 | 861 | [
"DDInter513",
"DDInter1601"
] | Dexamethasone | Ripretinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
1220,
24,
861
]
],
[
[
1220,
24,
351
],
[
351,
24,
861
]
],
[
[
1220,
25,
1456
],
[
1456,
24,
861
]
],
[
[
1220,
63,
1051
],
[
1051,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Dexamethasone may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may ... |
DB00736 | DB15093 | 660 | 1,654 | [
"DDInter676",
"DDInter1698"
] | Esomeprazole | Somapacitan | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
660,
24,
1654
]
],
[
[
660,
62,
168
],
[
168,
23,
1654
]
],
[
[
660,
1,
1215
],
[
1215,
24,
1654
]
],
[
[
660,
63,
883
],
[
883,
... | [
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[... | Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Esomeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that ... |
DB00468 | DB11793 | 1,424 | 738 | [
"DDInter1557",
"DDInter1297"
] | Quinine | Niraparib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1424,
24,
738
]
],
[
[
1424,
24,
1213
],
[
1213,
24,
738
]
],
[
[
1424,
25,
463
],
[
463,
24,
738
]
],
[
[
1424,
24,
1619
],
[
1619,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Das... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Quinine may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may cause a moderat... |
DB00350 | DB00697 | 1,214 | 876 | [
"DDInter1226",
"DDInter1821"
] | Minoxidil | Tizanidine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Major | 2 | [
[
[
1214,
25,
876
]
],
[
[
1214,
24,
1617
],
[
1617,
1,
876
]
],
[
[
1214,
7,
2384
],
[
2384,
46,
876
]
],
[
[
1214,
24,
401
],
[
401,
... | [
[
[
"Minoxidil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[
"Apracloni... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Tizanidine (Compound)
Minoxidil (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Tizanidine (Compound)
Minoxidil may cause a moderate interaction that could ... |
DB00214 | DB01172 | 1,028 | 416 | [
"DDInter1836",
"DDInter1004"
] | Torasemide | Kanamycin | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Major | 2 | [
[
[
1028,
25,
416
]
],
[
[
1028,
24,
355
],
[
355,
1,
416
]
],
[
[
1028,
7,
2216
],
[
2216,
46,
416
]
],
[
[
1028,
21,
28680
],
[
28680,
... | [
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose (Compound) resembles Kanamycin (Compound)
Torasemide (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Kanamycin (Compound)
Torasemide (Compound) causes Rash (Side Effect) and Rash (Side... |
DB00313 | DB08870 | 556 | 850 | [
"DDInter1913",
"DDInter228"
] | Valproic acid | Brentuximab vedotin | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
556,
24,
850
]
],
[
[
556,
24,
267
],
[
267,
24,
850
]
],
[
[
556,
24,
1033
],
[
1033,
63,
850
]
],
[
[
556,
63,
305
],
[
305,
2... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Alpeli... |
DB06273 | DB09276 | 980 | 381 | [
"DDInter1824",
"DDInter1682"
] | Tocilizumab | Sodium aurothiomalate | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no valu... | Moderate | 1 | [
[
[
980,
24,
381
]
],
[
[
980,
64,
1683
],
[
1683,
24,
381
]
],
[
[
980,
63,
491
],
[
491,
24,
381
]
],
[
[
980,
24,
1626
],
[
1626,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
... | Tocilizumab may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a... |
DB00992 | DB11363 | 842 | 1,276 | [
"DDInter1182",
"DDInter39"
] | Methyl aminolevulinate (topical) | Alectinib | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
842,
24,
1276
]
],
[
[
842,
63,
612
],
[
612,
24,
1276
]
],
[
[
842,
75,
213
],
[
213,
25,
1276
]
],
[
[
842,
63,
612
],
[
612,
... | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vert... | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin and Verteporfin may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01114 | DB01219 | 272 | 716 | [
"DDInter362",
"DDInter473"
] | Chlorpheniramine | Dantrolene | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
272,
24,
716
]
],
[
[
272,
6,
8374
],
[
8374,
45,
716
]
],
[
[
272,
21,
28698
],
[
28698,
60,
716
]
],
[
[
272,
24,
1609
],
[
1609,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} ... | Chlorpheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dantrolene (Compound)
Chlorpheniramine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dantrolene (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pen... |
DB00365 | DB01229 | 839 | 973 | [
"DDInter842",
"DDInter1377"
] | Grepafloxacin | Paclitaxel | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
839,
24,
973
]
],
[
[
839,
24,
310
],
[
310,
63,
973
]
],
[
[
839,
25,
1220
],
[
1220,
63,
973
]
],
[
[
839,
62,
134
],
[
134,
2... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Grepafloxacin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethas... |
DB09098 | DB15233 | 98 | 1,650 | [
"DDInter1700",
"DDInter142"
] | Somatrem | Avapritinib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Moderate | 1 | [
[
[
98,
24,
1650
]
],
[
[
98,
63,
1478
],
[
1478,
24,
1650
]
],
[
[
98,
64,
1101
],
[
1101,
24,
1650
]
],
[
[
98,
24,
159
],
[
159,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Somatrem may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a mod... |
DB08880 | DB10343 | 1,510 | 962 | [
"DDInter1771",
"DDInter160"
] | Teriflunomide | Bacillus calmette-guerin substrain tice live antigen | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
1510,
25,
962
]
],
[
[
1510,
64,
617
],
[
617,
24,
962
]
],
[
[
1510,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1510,
25,
270
],
[
270,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonid... | Teriflunomide may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Teriflunomide may lead to a major life threatening interaction when taken with Eta... |
DB00393 | DB06292 | 854 | 549 | [
"DDInter1295",
"DDInter474"
] | Nimodipine | Dapagliflozin | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
854,
24,
549
]
],
[
[
854,
24,
1344
],
[
1344,
40,
549
]
],
[
[
854,
6,
8374
],
[
8374,
45,
549
]
],
[
[
854,
21,
28787
],
[
28787,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Nimodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Nimodipine (Compound) causes Dermatitis (Side Effect) ... |
DB06168 | DB14443 | 1,531 | 987 | [
"DDInter281",
"DDInter1931"
] | Canakinumab | Vibrio cholerae CVD 103-HgR strain live antigen | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1531,
24,
987
]
],
[
[
1531,
24,
1480
],
[
1480,
24,
987
]
],
[
[
1531,
63,
141
],
[
141,
24,
987
]
],
[
[
1531,
25,
1583
],
[
1583,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Canakinumab may cause a moderate interaction that could exacerbate diseases wh... |
DB06292 | DB15093 | 549 | 1,654 | [
"DDInter474",
"DDInter1698"
] | Dapagliflozin | Somapacitan | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
549,
24,
1654
]
],
[
[
549,
63,
168
],
[
168,
23,
1654
]
],
[
[
549,
63,
176
],
[
176,
24,
1654
]
],
[
[
549,
62,
467
],
[
467,
... | [
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine... |
DB00065 | DB11952 | 581 | 800 | [
"DDInter923",
"DDInter612"
] | Infliximab | Duvelisib | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
581,
25,
800
]
],
[
[
581,
25,
310
],
[
310,
24,
800
]
],
[
[
581,
24,
467
],
[
467,
24,
800
]
],
[
[
581,
25,
1476
],
[
1476,
6... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} ... | Infliximab may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cau... |
DB00074 | DB10989 | 1,309 | 496 | [
"DDInter166",
"DDInter858"
] | Basiliximab | Hepatitis A Vaccine | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermenta... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1309,
24,
496
]
],
[
[
1309,
24,
4
],
[
4,
24,
496
]
],
[
[
1309,
25,
976
],
[
976,
24,
496
]
],
[
[
1309,
24,
270
],
[
270,
63,... | [
[
[
"Basiliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Basiliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepe... | Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Basiliximab may lead to a major life threatening interaction when taken ... |
DB00526 | DB01268 | 1,555 | 1,151 | [
"DDInter1355",
"DDInter1731"
] | Oxaliplatin | Sunitinib | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1555,
24,
1151
]
],
[
[
1555,
6,
17404
],
[
17404,
45,
1151
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
1151
]
],
[
[
1555,
24,
112
],
[
11... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Oxaliplatin",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
... | Oxaliplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Sunitinib (Compound)
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Oxaliplatin ... |
DB08868 | DB11627 | 1,011 | 1,367 | [
"DDInter737",
"DDInter860"
] | Fingolimod | Hepatitis B Vaccine (Recombinant) | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
1011,
24,
1367
]
],
[
[
1011,
64,
1083
],
[
1083,
24,
1367
]
],
[
[
1011,
25,
1480
],
[
1480,
24,
1367
]
],
[
[
1011,
25,
119
],
[
119... | [
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
]... | Fingolimod may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Fingolimod may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib ma... |
DB01149 | DB09472 | 851 | 1,383 | [
"DDInter1274",
"DDInter1693"
] | Nefazodone | Sodium sulfate | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
851,
24,
1383
]
],
[
[
851,
24,
609
],
[
609,
24,
1383
]
],
[
[
851,
63,
600
],
[
600,
24,
1383
]
],
[
[
851,
25,
477
],
[
477,
... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazo... |
DB00876 | DB06691 | 1,414 | 849 | [
"DDInter658",
"DDInter1155"
] | Eprosartan | Mepyramine | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1414,
24,
849
]
],
[
[
1414,
63,
1648
],
[
1648,
24,
849
]
],
[
[
1414,
24,
407
],
[
407,
63,
849
]
],
[
[
1414,
24,
1376
],
[
1376,
... | [
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may... |
DB08820 | DB09075 | 1,478 | 498 | [
"DDInter997",
"DDInter621"
] | Ivacaftor | Edoxaban | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
1478,
25,
498
]
],
[
[
1478,
63,
311
],
[
311,
24,
498
]
],
[
[
1478,
24,
321
],
[
321,
63,
498
]
],
[
[
1478,
64,
1623
],
[
1623,
... | [
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
],
[
"Valdecoxib",
... | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selumetin... |
DB09082 | DB12245 | 659 | 823 | [
"DDInter1934",
"DDInter1863"
] | Vilanterol | Triclabendazole | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
659,
24,
823
]
],
[
[
659,
24,
1612
],
[
1612,
24,
823
]
],
[
[
659,
63,
1010
],
[
1010,
24,
823
]
],
[
[
659,
24,
1619
],
[
1619,
... | [
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
... | Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and... |
DB00290 | DB00532 | 329 | 208 | [
"DDInter219",
"DDInter1152"
] | Bleomycin | Mephenytoin | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Moderate | 1 | [
[
[
329,
24,
208
]
],
[
[
329,
25,
908
],
[
908,
63,
208
]
],
[
[
329,
63,
599
],
[
599,
24,
208
]
],
[
[
329,
24,
4
],
[
4,
63,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
... | Bleomycin may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a... |
DB00470 | DB11130 | 530 | 407 | [
"DDInter601",
"DDInter1344"
] | Dronabinol | Opium | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
530,
24,
407
]
],
[
[
530,
24,
409
],
[
409,
24,
407
]
],
[
[
530,
63,
558
],
[
558,
24,
407
]
],
[
[
530,
24,
418
],
[
418,
63,... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may ... |
DB00959 | DB08882 | 1,486 | 1,281 | [
"DDInter1191",
"DDInter1070"
] | Methylprednisolone | Linagliptin | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1486,
24,
1281
]
],
[
[
1486,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1486,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
1486,
21,
30552
],
[
305... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Methylprednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Methylprednisolone (Compound) causes Diabetic (S... |
DB06441 | DB11793 | 936 | 738 | [
"DDInter283",
"DDInter1297"
] | Cangrelor | Niraparib | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
936,
24,
738
]
],
[
[
936,
64,
1213
],
[
1213,
24,
738
]
],
[
[
936,
63,
848
],
[
848,
24,
738
]
],
[
[
936,
25,
802
],
[
802,
2... | [
[
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Cangrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Cangrelor may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moder... |
DB00322 | DB00987 | 141 | 1,224 | [
"DDInter742",
"DDInter461"
] | Floxuridine | Cytarabine (liposomal) | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Cytarabine can cause developmental toxicity according to an independent committee of scientific and health experts. | Moderate | 1 | [
[
[
141,
24,
1224
]
],
[
[
141,
1,
903
],
[
903,
40,
1224
]
],
[
[
141,
7,
7806
],
[
7806,
46,
1224
]
],
[
[
141,
18,
5571
],
[
5571,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Floxuridine",
"{u} (Compound) resembles {v} (Compound)",
"Decitabine"
],
[
"Decitabine",
"{u} (Compound) resemb... | Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Floxuridine (Compound) resembles Decitabine (Compound) and Decitabine (Compound) resembles Cytarabine (Compound)
Floxuridine (Compound) upregulates INPP1 (Gene) and INPP1 (Gene) is upregulated by Cytarabine (Compound)... |
DB00218 | DB01177 | 1,176 | 77 | [
"DDInter1247",
"DDInter904"
] | Moxifloxacin | Idarubicin | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
1176,
25,
77
]
],
[
[
1176,
21,
28931
],
[
28931,
60,
77
]
],
[
[
1176,
1,
1467
],
[
1467,
23,
77
]
],
[
[
1176,
23,
112
],
[
112,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side Effect) is caused by {... | Moxifloxacin (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Idarubicin (Compound)
Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Moxifloxacin may cause a minor interaction... |
DB09312 | DB15091 | 967 | 676 | [
"DDInter103",
"DDInter1901"
] | Antilymphocyte immunoglobulin (horse) | Upadacitinib | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
967,
25,
676
]
],
[
[
967,
23,
1193
],
[
1193,
23,
676
]
],
[
[
967,
24,
1430
],
[
1430,
24,
676
]
],
[
[
967,
63,
1184
],
[
1184,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects when taken with {... | Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that cou... |
DB00375 | DB01024 | 1,037 | 1,096 | [
"DDInter433",
"DDInter1252"
] | Colestipol | Mycophenolic acid | Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally o... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Major | 2 | [
[
[
1037,
25,
1096
]
],
[
[
1037,
21,
28666
],
[
28666,
60,
1096
]
],
[
[
1037,
24,
629
],
[
629,
24,
1096
]
],
[
[
1037,
62,
964
],
[
964... | [
[
[
"Colestipol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Colestipol",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (... | Colestipol (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Mycophenolic acid (Compound)
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate... |
DB00762 | DB09268 | 613 | 1,662 | [
"DDInter973",
"DDInter1464"
] | Irinotecan | Picosulfuric acid | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
613,
24,
1662
]
],
[
[
613,
24,
484
],
[
484,
63,
1662
]
],
[
[
613,
63,
597
],
[
597,
24,
1662
]
],
[
[
613,
24,
1491
],
[
1491,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Chlorampheni... |
DB00186 | DB00405 | 905 | 128 | [
"DDInter1092",
"DDInter517"
] | Lorazepam | Dexbrompheniramine | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
905,
24,
128
]
],
[
[
905,
24,
662
],
[
662,
63,
128
]
],
[
[
905,
40,
686
],
[
686,
63,
128
]
],
[
[
905,
40,
523
],
[
523,
24,... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],... | Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Lorazepam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction th... |
DB00570 | DB11791 | 147 | 785 | [
"DDInter1936",
"DDInter287"
] | Vinblastine | Capmatinib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
147,
24,
785
]
],
[
[
147,
63,
1324
],
[
1324,
24,
785
]
],
[
[
147,
24,
310
],
[
310,
24,
785
]
],
[
[
147,
23,
896
],
[
896,
2... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and... |
DB08826 | DB09121 | 1,292 | 1,328 | [
"DDInter489",
"DDInter140"
] | Deferiprone | Aurothioglucose | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Major | 2 | [
[
[
1292,
25,
1328
]
],
[
[
1292,
64,
367
],
[
367,
24,
1328
]
],
[
[
1292,
25,
375
],
[
375,
24,
1328
]
],
[
[
1292,
25,
1480
],
[
1480,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Interferon alfacon-1"
],
[
"Interfer... | Deferiprone may lead to a major life threatening interaction when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Deferiprone may lead to a major life threatening interaction when taken with Certolizumab pegol and C... |
DB00694 | DB11978 | 51 | 124 | [
"DDInter485",
"DDInter822"
] | Daunorubicin | Glasdegib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
51,
24,
124
]
],
[
[
51,
23,
1247
],
[
1247,
23,
124
]
],
[
[
51,
24,
466
],
[
466,
62,
124
]
],
[
[
51,
24,
1079
],
[
1079,
24,... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Darolutami... |
DB00574 | DB00918 | 121 | 1,373 | [
"DDInter717",
"DDInter49"
] | Fenfluramine | Almotriptan | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that ... | Major | 2 | [
[
[
121,
25,
1373
]
],
[
[
121,
64,
767
],
[
767,
1,
1373
]
],
[
[
121,
25,
1541
],
[
1541,
40,
1373
]
],
[
[
121,
24,
1213
],
[
1213,
... | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Almotriptan"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zolmitriptan"
],
[
"Zolmitriptan",
... | Fenfluramine may lead to a major life threatening interaction when taken with Zolmitriptan and Zolmitriptan (Compound) resembles Almotriptan (Compound)
Fenfluramine may lead to a major life threatening interaction when taken with Naratriptan and Naratriptan (Compound) resembles Almotriptan (Compound)
Fenfluramine may c... |
DB01229 | DB08901 | 973 | 1,468 | [
"DDInter1378",
"DDInter1492"
] | Paclitaxel (protein-bound) | Ponatinib | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
973,
24,
1468
]
],
[
[
973,
24,
478
],
[
478,
24,
1468
]
],
[
[
973,
6,
10083
],
[
10083,
45,
1468
]
],
[
[
973,
7,
1972
],
[
1972,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Paclitaxel (Co... |
DB01001 | DB11915 | 688 | 1,293 | [
"DDInter1632",
"DDInter1909"
] | Salbutamol | Valbenazine | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
688,
24,
1293
]
],
[
[
688,
62,
112
],
[
112,
23,
1293
]
],
[
[
688,
63,
521
],
[
521,
24,
1293
]
],
[
[
688,
24,
401
],
[
401,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Gose... |
DB00322 | DB10989 | 141 | 496 | [
"DDInter742",
"DDInter858"
] | Floxuridine | Hepatitis A Vaccine | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
141,
24,
496
]
],
[
[
141,
24,
4
],
[
4,
24,
496
]
],
[
[
141,
24,
738
],
[
738,
63,
496
]
],
[
[
141,
25,
976
],
[
976,
24,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepe... | Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Floxuridine may cause a moderate interaction that could exacerbate disea... |
DB01124 | DB11967 | 1,411 | 710 | [
"DDInter1828",
"DDInter210"
] | Tolbutamide | Binimetinib | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1411,
24,
710
]
],
[
[
1411,
24,
1237
],
[
1237,
24,
710
]
],
[
[
1411,
24,
1619
],
[
1619,
63,
710
]
],
[
[
1411,
63,
463
],
[
463,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and ... |
DB01221 | DB09074 | 1,190 | 1,362 | [
"DDInter1007",
"DDInter1327"
] | Ketamine | Olaparib | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1190,
24,
1362
]
],
[
[
1190,
24,
1619
],
[
1619,
63,
1362
]
],
[
[
1190,
63,
1031
],
[
1031,
24,
1362
]
],
[
[
1190,
24,
1040
],
[
10... | [
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Ru... | Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline... |
DB01124 | DB01309 | 1,411 | 1,254 | [
"DDInter1828",
"DDInter933"
] | Tolbutamide | Insulin glulisine | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1411,
24,
1254
]
],
[
[
1411,
62,
333
],
[
333,
23,
1254
]
],
[
[
1411,
23,
721
],
[
721,
62,
1254
]
],
[
[
1411,
24,
1033
],
[
1033,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lipoic acid"
],
... | Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose ... |
DB06791 | DB09043 | 1,446 | 135 | [
"DDInter1021",
"DDInter36"
] | Lanreotide | Albiglutide | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1446,
24,
135
]
],
[
[
1446,
63,
1252
],
[
1252,
23,
135
]
],
[
[
1446,
63,
176
],
[
176,
24,
135
]
],
[
[
1446,
24,
1296
],
[
1296,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin... |
DB00877 | DB01244 | 629 | 762 | [
"DDInter1678",
"DDInter192"
] | Sirolimus | Bepridil | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Moderate | 1 | [
[
[
629,
24,
762
]
],
[
[
629,
63,
704
],
[
704,
1,
762
]
],
[
[
629,
63,
939
],
[
939,
40,
762
]
],
[
[
629,
6,
4973
],
[
4973,
45,... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
"F... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Bepridil (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Bepridil (Compound)
Siro... |
DB01105 | DB08875 | 222 | 1,618 | [
"DDInter1665",
"DDInter262"
] | Sibutramine | Cabozantinib | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
222,
24,
1618
]
],
[
[
222,
62,
723
],
[
723,
24,
1618
]
],
[
[
222,
23,
384
],
[
384,
63,
1618
]
],
[
[
222,
24,
1032
],
[
1032,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
],
[
... | Sibutramine may cause a minor interaction that can limit clinical effects when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib and Idelal... |
DB00526 | DB00582 | 1,555 | 1,622 | [
"DDInter1355",
"DDInter1946"
] | Oxaliplatin | Voriconazole | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Moderate | 1 | [
[
[
1555,
24,
1622
]
],
[
[
1555,
24,
1287
],
[
1287,
62,
1622
]
],
[
[
1555,
24,
663
],
[
663,
24,
1622
]
],
[
[
1555,
24,
1419
],
[
1419... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexat... |
DB09570 | DB14711 | 1,480 | 779 | [
"DDInter1002",
"DDInter1680"
] | Ixazomib | Smallpox (Vaccinia) Vaccine, Live | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1480,
25,
779
]
],
[
[
1480,
64,
1064
],
[
1064,
25,
779
]
],
[
[
1480,
63,
147
],
[
147,
25,
779
]
],
[
[
1480,
25,
1259
],
[
1259,
... | [
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladri... | Ixazomib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may ... |
DB00459 | DB01067 | 640 | 959 | [
"DDInter21",
"DDInter826"
] | Acitretin | Glipizide | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
640,
24,
959
]
],
[
[
640,
63,
245
],
[
245,
40,
959
]
],
[
[
640,
24,
1411
],
[
1411,
1,
959
]
],
[
[
640,
21,
30573
],
[
30573,
... | [
[
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
... |
DB00176 | DB08824 | 529 | 591 | [
"DDInter770",
"DDInter959"
] | Fluvoxamine | Ioflupane I-123 | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
529,
24,
591
]
],
[
[
529,
6,
2437
],
[
2437,
45,
591
]
],
[
[
529,
21,
29305
],
[
29305,
60,
591
]
],
[
[
529,
24,
401
],
[
401,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A3"
],
[
"SLC6A3",
"{u} (Gene) is bound by {v} (Comp... | Fluvoxamine (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Ioflupane I-123 (Compound)
Fluvoxamine (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Ioflupane I-123 (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Promet... |
DB00818 | DB11130 | 898 | 407 | [
"DDInter1538",
"DDInter1344"
] | Propofol | Opium | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
898,
24,
407
]
],
[
[
898,
24,
516
],
[
516,
24,
407
]
],
[
[
898,
63,
475
],
[
475,
24,
407
]
],
[
[
898,
23,
256
],
[
256,
24,... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"... | Propofol may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine ... |
DB00604 | DB12267 | 1,425 | 1,476 | [
"DDInter385",
"DDInter233"
] | Cisapride | Brigatinib | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1425,
24,
1476
]
],
[
[
1425,
25,
1612
],
[
1612,
23,
1476
]
],
[
[
1425,
24,
629
],
[
629,
24,
1476
]
],
[
[
1425,
25,
800
],
[
800,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir... | Cisapride may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a mo... |
DB00316 | DB01097 | 474 | 1,377 | [
"DDInter14",
"DDInter1033"
] | Acetaminophen | Leflunomide | Acetaminophen (paracetamol), also commonly known as _Tylenol_, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the ... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
474,
25,
1377
]
],
[
[
474,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
474,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
474,
24,
126
],
[
126,
... | [
[
[
"Acetaminophen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Acetaminophen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"... | Acetaminophen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Acetaminophen (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Acetaminophen may cause a moderate interaction that could exacerbate diseases when taken with Warf... |
DB00295 | DB01020 | 475 | 1,107 | [
"DDInter1244",
"DDInter990"
] | Morphine | Isosorbide mononitrate | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Isosorbide mononitrate is an organic nitrate with vasodilating properties. It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload.[L11698, L11743] Isosorbide mononitrate is an active metabolite of [isosorbide dinitrate]. Li... | Moderate | 1 | [
[
[
475,
24,
1107
]
],
[
[
475,
24,
426
],
[
426,
40,
1107
]
],
[
[
475,
6,
8374
],
[
8374,
45,
1107
]
],
[
[
475,
10,
11576
],
[
11576,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isosorbide mononitrate"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isosorbide dinitrat... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Isosorbide dinitrate and Isosorbide dinitrate (Compound) resembles Isosorbide mononitrate (Compound)
Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isosorbide mononitrate (Compound)
Morphine (Compound) pallia... |
DB00867 | DB01254 | 1,052 | 1,213 | [
"DDInter1606",
"DDInter484"
] | Ritodrine | Dasatinib | Adrenergic beta-agonist used to control premature labor. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
1052,
24,
1213
]
],
[
[
1052,
7,
3422
],
[
3422,
46,
1213
]
],
[
[
1052,
6,
3576
],
[
3576,
57,
1213
]
],
[
[
1052,
18,
2183
],
[
2183... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Ritodrine",
"{u} (Compound) upregulates {v} (Gene)",
"SATB1"
],
[
"SATB1",
"{u} (Gene) is upregulated by {v} (Comp... | Ritodrine (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Dasatinib (Compound)
Ritodrine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is downregulated by Dasatinib (Compound)
Ritodrine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Dasatinib (Compound)
Ritodrine may ... |
DB01064 | DB01367 | 1,148 | 1,163 | [
"DDInter987",
"DDInter1572"
] | Isoprenaline | Rasagiline | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Moderate | 1 | [
[
[
1148,
24,
1163
]
],
[
[
1148,
21,
28714
],
[
28714,
60,
1163
]
],
[
[
1148,
63,
590
],
[
590,
24,
1163
]
],
[
[
1148,
24,
1520
],
[
15... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is ca... | Isoprenaline (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Rasagiline (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with... |
DB01284 | DB10583 | 1,042 | 949 | [
"DDInter1782",
"DDInter415"
] | Tetracosactide | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
1042,
24,
949
]
],
[
[
1042,
63,
589
],
[
589,
24,
949
]
],
[
[
1042,
64,
1377
],
[
1377,
24,
949
]
],
[
[
1042,
25,
1259
],
[
1259,
... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate disease... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Tetracosactide may lead to a major life threatening interact... |
DB00860 | DB12095 | 891 | 179 | [
"DDInter1513",
"DDInter1760"
] | Prednisolone | Telotristat ethyl | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
891,
24,
179
]
],
[
[
891,
24,
1517
],
[
1517,
24,
179
]
],
[
[
891,
40,
1547
],
[
1547,
24,
179
]
],
[
[
891,
24,
283
],
[
283,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Prednisolone (Compound) resembles Exemestane (Compound) and Exemestane may cause a moderate interac... |
DB11057 | DB12245 | 720 | 823 | [
"DDInter1223",
"DDInter1863"
] | Mineral oil | Triclabendazole | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
720,
24,
823
]
],
[
[
720,
24,
1612
],
[
1612,
24,
823
]
],
[
[
720,
63,
1010
],
[
1010,
24,
823
]
],
[
[
720,
24,
180
],
[
180,
... | [
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
... | Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine a... |
DB00372 | DB00629 | 999 | 390 | [
"DDInter1793",
"DDInter844"
] | Thiethylperazine | Guanabenz | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem] | Moderate | 1 | [
[
[
999,
24,
390
]
],
[
[
999,
24,
1364
],
[
1364,
40,
390
]
],
[
[
999,
24,
549
],
[
549,
63,
390
]
],
[
[
999,
63,
1648
],
[
1648,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanabenz"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine and Guanfacine (Compound) resembles Guanabenz (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate inter... |
DB00620 | DB01232 | 175 | 1,327 | [
"DDInter1855",
"DDInter1640"
] | Triamcinolone | Saquinavir | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Major | 2 | [
[
[
175,
25,
1327
]
],
[
[
175,
64,
798
],
[
798,
40,
1327
]
],
[
[
175,
25,
915
],
[
915,
40,
1327
]
],
[
[
175,
6,
8374
],
[
8374,
... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
... | Triamcinolone may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Triamcinolone may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Compound)
Triamcinolone (Compound)... |
DB00023 | DB00252 | 305 | 362 | [
"DDInter127",
"DDInter1460"
] | Asparaginase Escherichia coli | Phenytoin | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Moderate | 1 | [
[
[
305,
24,
362
]
],
[
[
305,
24,
126
],
[
126,
63,
362
]
],
[
[
305,
24,
1236
],
[
1236,
40,
362
]
],
[
[
305,
25,
1101
],
[
1101,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when... |
DB00496 | DB01114 | 194 | 272 | [
"DDInter480",
"DDInter362"
] | Darifenacin | Chlorpheniramine | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
194,
24,
272
]
],
[
[
194,
24,
849
],
[
849,
63,
272
]
],
[
[
194,
63,
128
],
[
128,
24,
272
]
],
[
[
194,
6,
12523
],
[
12523,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Dexbromphenir... |
DB04855 | DB06274 | 540 | 574 | [
"DDInter602",
"DDInter59"
] | Dronedarone | Alvimopan | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period. | Moderate | 1 | [
[
[
540,
24,
574
]
],
[
[
540,
21,
29113
],
[
29113,
60,
574
]
],
[
[
540,
24,
214
],
[
214,
63,
574
]
],
[
[
540,
25,
129
],
[
129,
... | [
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alvimopan"
]
],
[
[
"Dronedarone",
"{u} (Compound) causes {v} (Side Effect)",
"Hypokalaemia"
],
[
"Hypokalaemia",
"{u} (Side Effect) ... | Dronedarone (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Alvimopan (Compound)
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken w... |
DB06605 | DB11732 | 1,409 | 1,097 | [
"DDInter108",
"DDInter1027"
] | Apixaban | Lasmiditan | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1409,
24,
1097
]
],
[
[
1409,
24,
971
],
[
971,
63,
1097
]
],
[
[
1409,
63,
478
],
[
478,
24,
1097
]
],
[
[
1409,
24,
384
],
[
384,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotin... |
DB00731 | DB00960 | 1,144 | 887 | [
"DDInter1269",
"DDInter1471"
] | Nateglinide | Pindolol | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Moderate | 1 | [
[
[
1144,
24,
887
]
],
[
[
1144,
24,
819
],
[
819,
40,
887
]
],
[
[
1144,
24,
1148
],
[
1148,
63,
887
]
],
[
[
1144,
63,
88
],
[
88,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that c... |
DB00031 | DB06779 | 20 | 365 | [
"DDInter1764",
"DDInter470"
] | Tenecteplase | Dalteparin | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
20,
25,
365
]
],
[
[
20,
23,
539
],
[
539,
62,
365
]
],
[
[
20,
24,
954
],
[
954,
24,
365
]
],
[
[
20,
24,
1496
],
[
1496,
63,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",... | Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril m... |
DB00238 | DB00682 | 188 | 126 | [
"DDInter1285",
"DDInter1951"
] | Nevirapine | Warfarin | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
188,
24,
126
]
],
[
[
188,
6,
7950
],
[
7950,
45,
126
]
],
[
[
188,
62,
168
],
[
168,
23,
126
]
],
[
[
188,
24,
663
],
[
663,
23... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Nevirapine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Warfarin (Compound)
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin
Nevirapine may cause a mod... |
DB00443 | DB00982 | 251 | 1,517 | [
"DDInter195",
"DDInter991"
] | Betamethasone | Isotretinoin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Moderate | 1 | [
[
[
251,
24,
1517
]
],
[
[
251,
18,
2874
],
[
2874,
46,
1517
]
],
[
[
251,
7,
1933
],
[
1933,
46,
1517
]
],
[
[
251,
18,
15501
],
[
15501,... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Betamethasone",
"{u} (Compound) downregulates {v} (Gene)",
"CTSL"
],
[
"CTSL",
"{u} (Gene) is upregulated b... | Betamethasone (Compound) downregulates CTSL (Gene) and CTSL (Gene) is upregulated by Isotretinoin (Compound)
Betamethasone (Compound) upregulates TNFAIP3 (Gene) and TNFAIP3 (Gene) is upregulated by Isotretinoin (Compound)
Betamethasone (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Isotret... |
DB09043 | DB14276 | 135 | 1,631 | [
"DDInter36",
"DDInter1892"
] | Albiglutide | Turmeric | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Moderate | 1 | [
[
[
135,
24,
1631
]
],
[
[
135,
62,
126
],
[
126,
23,
1631
]
],
[
[
135,
63,
473
],
[
473,
24,
1631
]
],
[
[
135,
62,
1647
],
[
1647,
... | [
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Turmeric"
]
],
[
[
"Albiglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
... | Albiglutide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Turmeric
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide m... |
DB00270 | DB08899 | 1,428 | 129 | [
"DDInter993",
"DDInter649"
] | Isradipine | Enzalutamide | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
1428,
25,
129
]
],
[
[
1428,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1428,
21,
28703
],
[
28703,
60,
129
]
],
[
[
1428,
24,
1512
],
[
1512... | [
[
[
"Isradipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Isradipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzal... | Isradipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Isradipine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Di... |
DB00357 | DB12141 | 1,051 | 971 | [
"DDInter71",
"DDInter817"
] | Aminoglutethimide | Gilteritinib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1051,
24,
971
]
],
[
[
1051,
24,
1135
],
[
1135,
23,
971
]
],
[
[
1051,
24,
466
],
[
466,
62,
971
]
],
[
[
1051,
24,
700
],
[
700,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Darolutam... |
DB00962 | DB08899 | 1,639 | 129 | [
"DDInter1957",
"DDInter649"
] | Zaleplon | Enzalutamide | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1639,
24,
129
]
],
[
[
1639,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1639,
21,
28703
],
[
28703,
60,
129
]
],
[
[
1639,
62,
1101
],
[
1101... | [
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Zaleplon",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Zaleplon (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Zaleplon (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Zaleplon may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene... |
DB00364 | DB00731 | 417 | 1,144 | [
"DDInter1717",
"DDInter1269"
] | Sucralfate | Nateglinide | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
417,
24,
1144
]
],
[
[
417,
6,
1829
],
[
1829,
45,
1144
]
],
[
[
417,
23,
624
],
[
624,
63,
1144
]
],
[
[
417,
23,
17
],
[
17,
2... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Sucralfate",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
... | Sucralfate (Compound) binds ALB (Gene) and ALB (Gene) is bound by Nateglinide (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Liotrix and Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Sucralfate may cause a minor i... |
DB00444 | DB09121 | 63 | 1,328 | [
"DDInter1765",
"DDInter140"
] | Teniposide | Aurothioglucose | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Moderate | 1 | [
[
[
63,
24,
1328
]
],
[
[
63,
63,
367
],
[
367,
24,
1328
]
],
[
[
63,
64,
581
],
[
581,
24,
1328
]
],
[
[
63,
24,
310
],
[
310,
24,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Teniposide may lead to a major life threatening interaction when taken with Infliximab ... |
DB01191 | DB15233 | 1,039 | 1,650 | [
"DDInter518",
"DDInter142"
] | Dexfenfluramine | Avapritinib | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Moderate | 1 | [
[
[
1039,
24,
1650
]
],
[
[
1039,
24,
1374
],
[
1374,
24,
1650
]
],
[
[
1039,
64,
121
],
[
121,
24,
1650
]
],
[
[
1039,
63,
1512
],
[
1512... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Dexfenfluramine may lead to a major life threatening interaction when taken with Fenfluramine and Fenflu... |
DB00564 | DB08820 | 1,236 | 1,478 | [
"DDInter293",
"DDInter997"
] | Carbamazepine | Ivacaftor | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Major | 2 | [
[
[
1236,
25,
1478
]
],
[
[
1236,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1236,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
1236,
40,
307
],
[
30... | [
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Iv... | Carbamazepine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Carbamazepine (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Carbamazepine (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction th... |
DB00675 | DB01191 | 888 | 1,039 | [
"DDInter1744",
"DDInter518"
] | Tamoxifen | Dexfenfluramine | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Major | 2 | [
[
[
888,
25,
1039
]
],
[
[
888,
6,
10215
],
[
10215,
45,
1039
]
],
[
[
888,
6,
5182
],
[
5182,
46,
1039
]
],
[
[
888,
18,
4360
],
[
4360,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"De... | Tamoxifen (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Dexfenfluramine (Compound)
Tamoxifen (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Dexfenfluramine (Compound)
Tamoxifen (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Dexfenfluramine (Compound)
Tamoxife... |
DB01365 | DB09082 | 280 | 659 | [
"DDInter1151",
"DDInter1934"
] | Mephentermine | Vilanterol | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
280,
24,
659
]
],
[
[
280,
24,
1296
],
[
1296,
63,
659
]
],
[
[
280,
40,
1161
],
[
1161,
24,
659
]
],
[
[
280,
24,
1450
],
[
1450,
... | [
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
... | Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Mephentermine (Compound) resembles Selegiline (Compound) and Selegiline may cause a moderate inte... |
DB06441 | DB10344 | 936 | 992 | [
"DDInter283",
"DDInter818"
] | Cangrelor | Ginger | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
936,
24,
992
]
],
[
[
936,
64,
1578
],
[
1578,
24,
992
]
],
[
[
936,
25,
1421
],
[
1421,
63,
992
]
],
[
[
936,
25,
802
],
[
802,
... | [
[
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Cangrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
... | Cangrelor may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Cangrelor may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction ... |
DB01285 | DB06718 | 708 | 1,687 | [
"DDInter445",
"DDInter1709"
] | Corticotropin | Stanozolol | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes. | Moderate | 1 | [
[
[
708,
24,
1687
]
],
[
[
708,
24,
1546
],
[
1546,
1,
1687
]
],
[
[
708,
63,
1561
],
[
1561,
40,
1687
]
],
[
[
708,
63,
155
],
[
155,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Stanozolol (Compound)
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resemb... |
DB00304 | DB11828 | 1,657 | 1,406 | [
"DDInter508",
"DDInter1281"
] | Desogestrel | Neratinib | Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activ... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
1657,
24,
1406
]
],
[
[
1657,
24,
392
],
[
392,
24,
1406
]
],
[
[
1657,
1,
1197
],
[
1197,
24,
1406
]
],
[
[
1657,
23,
14
],
[
14,
... | [
[
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
... | Desogestrel may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Desogestrel (Compound) resembles Norethisterone (Compound) and Norethisterone may cause a moderate interaction tha... |
DB00564 | DB01110 | 1,236 | 86 | [
"DDInter293",
"DDInter1209"
] | Carbamazepine | Miconazole | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
1236,
24,
86
]
],
[
[
1236,
6,
10215
],
[
10215,
45,
86
]
],
[
[
1236,
18,
10375
],
[
10375,
57,
86
]
],
[
[
1236,
21,
29122
],
[
2912... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Com... | Carbamazepine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Miconazole (Compound)
Carbamazepine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Miconazole (Compound)
Carbamazepine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is... |
DB01320 | DB06273 | 651 | 980 | [
"DDInter783",
"DDInter1824"
] | Fosphenytoin | Tocilizumab | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
651,
24,
980
]
],
[
[
651,
24,
309
],
[
309,
24,
980
]
],
[
[
651,
63,
973
],
[
973,
24,
980
]
],
[
[
651,
24,
850
],
[
850,
63,... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and... |
DB00916 | DB12141 | 112 | 971 | [
"DDInter1202",
"DDInter817"
] | Metronidazole | Gilteritinib | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Minor | 0 | [
[
[
112,
23,
971
]
],
[
[
112,
23,
1247
],
[
1247,
23,
971
]
],
[
[
112,
62,
485
],
[
485,
24,
971
]
],
[
[
112,
23,
730
],
[
730,
6... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pentami... |
DB04951 | DB14575 | 187 | 733 | [
"DDInter1477",
"DDInter674"
] | Pirfenidone | Eslicarbazepine | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
187,
24,
733
]
],
[
[
187,
62,
168
],
[
168,
23,
733
]
],
[
[
187,
24,
985
],
[
985,
24,
733
]
],
[
[
187,
25,
1297
],
[
1297,
2... | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Pirfenidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
... | Pirfenidone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Os... |
DB06723 | DB09020 | 115 | 28 | [
"DDInter58",
"DDInter212"
] | Aluminum hydroxide | Bisacodyl | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
115,
24,
28
]
],
[
[
115,
63,
739
],
[
739,
24,
28
]
],
[
[
115,
62,
870
],
[
870,
24,
28
]
],
[
[
115,
24,
786
],
[
786,
24,
... | [
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin... | Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Flud... |
DB00388 | DB04843 | 1,636 | 1,511 | [
"DDInter1453",
"DDInter1149"
] | Phenylephrine | Mepenzolate | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1636,
24,
1511
]
],
[
[
1636,
24,
1192
],
[
1192,
24,
1511
]
],
[
[
1636,
63,
357
],
[
357,
24,
1511
]
],
[
[
1636,
21,
28975
],
[
289... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Benzat... |
DB01591 | DB12332 | 667 | 1,619 | [
"DDInter1696",
"DDInter1626"
] | Solifenacin | Rucaparib | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
667,
24,
1619
]
],
[
[
667,
62,
112
],
[
112,
23,
1619
]
],
[
[
667,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
667,
63,
1419
],
[
1419,
... | [
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Solifenacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid ... |
DB00011 | DB00352 | 1,451 | 482 | [
"DDInter944",
"DDInter1814"
] | Interferon alfa-n1 | Tioguanine | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
1451,
24,
482
]
],
[
[
1451,
24,
1439
],
[
1439,
63,
482
]
],
[
[
1451,
25,
1648
],
[
1648,
24,
482
]
],
[
[
1451,
24,
912
],
[
912,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Aldesleukin and Alde... |
DB01193 | DB08907 | 819 | 1,344 | [
"DDInter12",
"DDInter280"
] | Acebutolol | Canagliflozin | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
819,
24,
1344
]
],
[
[
819,
24,
549
],
[
549,
1,
1344
]
],
[
[
819,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
819,
21,
28646
],
[
28646,
... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Acebutolol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Acebutolol (Compound) causes Unspecified disorder of ski... |
DB00215 | DB01176 | 1,230 | 537 | [
"DDInter388",
"DDInter453"
] | Citalopram | Cyclizine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
1230,
24,
537
]
],
[
[
1230,
24,
1242
],
[
1242,
24,
537
]
],
[
[
1230,
24,
104
],
[
104,
1,
537
]
],
[
[
1230,
6,
10104
],
[
10104,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
... | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methd... |
DB00333 | DB12130 | 576 | 1,017 | [
"DDInter1166",
"DDInter1094"
] | Methadone | Lorlatinib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
576,
25,
1017
]
],
[
[
576,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
576,
24,
976
],
[
976,
24,
1017
]
],
[
[
576,
25,
1491
],
[
1491,
... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",... | Methadone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitin... |
DB01229 | DB09098 | 973 | 98 | [
"DDInter1377",
"DDInter1700"
] | Paclitaxel | Somatrem | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
973,
24,
98
]
],
[
[
973,
63,
168
],
[
168,
23,
98
]
],
[
[
973,
63,
671
],
[
671,
24,
98
]
],
[
[
973,
24,
1671
],
[
1671,
24,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastat... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.